In the Phase 2 TEASE 2 trial, gildeuretinol was well tolerated and showed promising trends in slowing ellipsoid zone loss and preserving low-luminance visual acuity in patients with Stargardt disease.

Ken Beckman, MD, FACS, is a corneal specialist and clinical assistant professor at The Ohio State University. At the 2025 ...

A key area of practice management and sustainability initiatives is ensuring that waste is reduced whenever possible. In a study presented at the AAO 2025 meeting, Mark Brower, DO, researched whether ...

DAVIO-2 for wet AMD and VERONA for DME. In the DAVIO-2 trial, patients previously treated with approximately 10 injections in ...

The American Academy of Ophthalmology (AAO) is hosting its annual scientific meeting in Orlando, Florida from October 17 ...

A new study published in Experimental Eye Research reported that the preclinical results achieved with SPG302 (Spinogenix, ...